✦ LIBER ✦

Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-α

✍ Scribed by Vuoristo, M.; Gröhn, P.; Kumpulainen, E.; Korpela, M.

Book ID: 123356112
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 134 KB
Volume: 30
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(94)90278-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interferon α-2a in combinati

Recombinant interferon α-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients

✍ Ilan G. Ron; Moshe J. Inbar; Mordechai Gutman; Ofer Merimsky; Samario Chaitchik 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 987 KB

Cisplatin, dacarbazine, and fotemustine

Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma : A multicenter Phase II study of the Southern Italy Cooperative Oncology Group

✍ Antonio Daponte; Paolo A. Ascierto; Adriano Gravina; Maria Teresa Melucci; Giuse 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Chemoimmunotherapy with dacarbazine, cis

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

✍ C.J.A. Punt; S. Suciu; M.A. Gore; J. Koller; W.H.J. Kruit; J. Thomas; P. Patel; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Randomized trial of treatment with cispl

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma : A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

✍ Thierry Dorval; Sylvie Négrier; Christine Chevreau; Marie-Françoise Avril; Danie 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (il-2) with or without interferon-alpha-2a (ifn) in patients with metastatic melanoma. ## Methods: On